Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Details for Australian Patent Application No. 2012211347 (hide)

Owner Alexion Pharmaceuticals, Inc.

Inventors Bowdish, Katherine S.; Kretz-Rommel, Anke; McWhirter, John

Agent Shelston IP

Pub. Number AU-A-2012211347

Parent 2005274785

Filing date 3 August 2012

Wipo publication date 23 August 2012

International Classifications

C07K 16/18 Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

A61K 39/00 Medicinal preparations containing antigens or antibodies

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61K 51/00 Preparations containing radioactive substances for use in therapy or testing

A61K 51/10 Preparations containing radioactive substances for use in therapy or testing

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/30 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 16/46 Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

G01N 33/53 Investigating or analysing materials by specific methods not covered by groups - Immunoassay

G01N 33/574 Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

16 August 2012 Complete Application Filed

23 August 2012 Application Open to Public Inspection

  Published as AU-A-2012211347

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012211348-Catalytic filter system

2012211346-Optimizing expression of active botulinum toxin type A